Immunome Inc
IMNM
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.79B
Close$
$7.26
63.2% downside
Current Fair Value
63.2% downsideOvervalued by 63.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.79 Billion |
|---|---|
| Enterprise Value | $1.21 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.43 |
| Beta | 2.07 |
| Outstanding Shares | 113,136,836 |
Return
| Return on Equity | -38.15% |
|---|---|
| Return on Assets | -36.24% |
| Return on Invested Capital | -38.63% |
Valuation & Multiples
| P/E Ratio | -9.44 |
|---|---|
| PEG | -32.22 |
| Price to Sales | - |
| Price to Book Ratio | 3.95 |
| Enterprise Value to Revenue | 301.98 |
| Enterprise Value to EBIT | -5.3 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.60
Average shareholder expectationRevenue Estimate
$222,222
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-0.51
Average shareholder expectationRevenue Estimate
$166,667
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 5.1033▲ 257.14% |
|---|---|
| Total Calls | 269,100▼ 71.11% |
| Total Puts | 1,373,300▼ 41.78% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 133.55%▼ 0.98% |
|---|---|
| Total Invested | $2.54B▲ 0.12% |
| Investors Holding | 205▲ 10.00% |
ESG Score
No data
About Immunome Inc
2,020 employeesImmunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company's initi...